Bibliotecas PUC-SP - Busca Integrada

Tumor heterogeneity in the clinic: is it a real problem?

Tekijä Filip Janku
Julkaisussa Therapeutic Advances in Medical Oncology (2014-03-01)

Deciding site of biopsy at metastatic relapse: reply

Tekijä Filip Janku
Julkaisussa Therapeutic Advances in Medical Oncology (2014-11-01)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Tekijä Jacob J. Adashek, Filip Janku, Razelle Kurzrock
Julkaisussa Cancers (2021-07-01)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?

Tekijä Aditya Shreenivas, Filip Janku, Mohamed A. Gouda, Hui-Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock
Julkaisussa npj Precision Oncology (2023-09-01)

382 Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: phase 2 basket study

Tekijä Filip Janku, Apostolia Tsimberidou, Diane Healey, Vincent O’Neill, Veronica Holley, Abha Adat, Ozgur Karakuzu, Greg Call, Gabriele Urschel
Julkaisussa Journal for ImmunoTherapy of Cancer (2020-11-01)

BRAF mutations in advanced cancers: clinical characteristics and outcomes.

Tekijä Hazem El-Osta, Gerald Falchook, Apostolia Tsimberidou, David Hong, Aung Naing, Kevin Kim, Sijin Wen, Filip Janku, Razelle Kurzrock
Julkaisussa PLoS ONE (2011-01-01)

418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastat...

Tekijä Filip Janku, Matthew Taylor, Michael Gordon, Cathy Eng, Antonio Jimeno, Joaquina Baranda, Ursula Matulonis, Martin Kornacker, Asha Kamat, Oliver Rosen
Julkaisussa Journal for ImmunoTherapy of Cancer (2020-11-01)

Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.

Tekijä Yunyun Jiang, Vivek Subbiah, Filip Janku, Joseph A Ludwig, Aung Naing, Robert S Benjamin, Robert E Brown, Pete Anderson, Razelle Kurzrock
Julkaisussa PLoS ONE (2014-01-01)

19 Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST

Tekijä Filip Janku, Josette Northcott, Sean Boyle, Richard Chen, Rachel Pyke, Charles Abbott, Eric Levy, Niamh Coleman, Fabio Navarro, Lee McDaniel
Julkaisussa Journal for ImmunoTherapy of Cancer (2021-11-01)

482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

Tekijä Judy Wang, Filip Janku, Manish Sharma, Johanna Bendell, Amit Mahipal, George Dranitsaris, Aleksandra Filipovic, Zev Wainber, Joseph Bolen, Eric Elenko, Christopher Korth
Julkaisussa Journal for ImmunoTherapy of Cancer (2021-11-01)

500 SYNB1891, a bacterium engineered to produce a STING agonist, demonstrates target engagement in humans following intratumoral injection

Tekijä Filip Janku, Jason Luke, Sarina Piha-Paul, Karl Lewis, James Strauss, Mary Varterasian, Anna Sokolovska, Richard Riese, Michael Armstrong, Claire Verschraegen, Aoife Brennan
Julkaisussa Journal for ImmunoTherapy of Cancer (2021-11-01)

397 Intra-tumor immunotherapy injections utilizing image guidance in interventional radiology: clinical trial experience at a tertiary care cancer center

Tekijä Sanjay Gupta, Vivek Subbiah, Sapna Patel, Adi Diab, Ravi Murthy, Aung Naing, Funda Meric-Bernstam, Filip Janku, Alda Tam, Timothy Yap, Rahul Sheth
Julkaisussa Journal for ImmunoTherapy of Cancer (2020-11-01)

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Tekijä Jeffrey A. How, Amir A. Jazaeri, Pamela T. Soliman, Nicole D. Fleming, Jing Gong, Sarina A. Piha-Paul, Filip Janku, Bettzy Stephen, Aung Naing
Julkaisussa Scientific Reports (2021-02-01)

484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

Tekijä Stephane Champiat, Aurélien Marabelle, Aung Naing, Filip Janku, Patricia LoRusso, David Béchard, Elena Garralda, Vladimir Galvao, Peter Grell, Richard Sachse, Joachim Kiemle-Kallee
Julkaisussa Journal for ImmunoTherapy of Cancer (2021-11-01)

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Tekijä Filip Janku, J Jack Lee, Apostolia M Tsimberidou, David S Hong, Aung Naing, Gerald S Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido-Laguna, Razelle Kurzrock
Julkaisussa PLoS ONE (2011-01-01)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors

Tekijä Shuyang Yao, Filip Janku, Kimberly Koenig, Apostolia Maria Tsimberidou, Sarina Anne Piha‐Paul, Nai Shi, John Stewart, Amanda Johnston, John Bomalaski, Funda Meric‐Bernstam, Siqing Fu
Julkaisussa Cancer Medicine (2022-01-01)

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

Tekijä Ignacio Garrido-Laguna, David S Hong, Filip Janku, Ly M Nguyen, Gerald S Falchook, Siqing Fu, Jenifer J Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock
Julkaisussa PLoS ONE (2012-01-01)

A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA

Tekijä Filip Janku, Helen J. Huang, David Y. Pereira, Masae Kobayashi, Chung Hei Chiu, S. Greg Call, Kristen T. Woodbury, Felix Chao, Daniel R. Marshak, Ricky Y. T. Chiu
Julkaisussa Scientific Reports (2021-10-01)

Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study

Tekijä Siqing Fu, Aung Naing, Filip Janku, Mingxuan Xu, Anas Alshawa, Nazanin Majd, Steven G Waguespack, Marta Penas-Prado, Carlos Kamiya-Matsuoka, Shaan M Raza, Ian E McCutcheon
Julkaisussa Journal for ImmunoTherapy of Cancer (2020-10-01)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Tekijä Roman Groisberg, David S. Hong, Amini Behrang, Kenneth Hess, Filip Janku, Sarina Piha-Paul, Aung Naing, Siqing Fu, Robert Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Conley, Funda Meric-Bernstam, Vivek Subbiah
Julkaisussa Journal for ImmunoTherapy of Cancer (2017-12-01)